Ironic case of hepatic dysfunction following the global withdrawal of sitaxentan

Internal Medicine Journal

Volumn 42, Issue 12, 2012, Pages 1351-1354

  Don, G W ^a   Joseph, F ^a   Celermajer, D S ^a   Corte, T J ^a  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

Hepatic dysfunction; Management; Pulmonary arterial hypertension; Sitaxentan; Systemic sclerosis

Indexed keywords

BOSENTAN; SILDENAFIL; SITAXSENTAN;

ADULT; ARTHRALGIA; ARTICLE; CASE REPORT; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPNEA; ELECTROCARDIOGRAM; EYE JAUNDICE; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HEART CATHETERIZATION; HEART RIGHT VENTRICLE FAILURE; HUMAN; HYPOPIGMENTATION; LIVER DYSFUNCTION; LIVER FUNCTION TEST; LUNG ARTERY PRESSURE; LUNG FUNCTION TEST; MONOTHERAPY; PEPTIC ULCER; PERIPHERAL EDEMA; PRIORITY JOURNAL; PULMONARY ARTERY OCCLUSION PRESSURE; PULMONARY HYPERTENSION; RAYNAUD PHENOMENON; SKINFOLD; SMOKING; THORAX RADIOGRAPHY; TRANSTHORACIC ECHOCARDIOGRAPHY; TRICUSPID VALVE REGURGITATION; UTERUS MYOMA;

ANTIHYPERTENSIVE AGENTS; FEMALE; HUMANS; HYPERTENSION, PULMONARY; ISOXAZOLES; LIVER; LIVER FUNCTION TESTS; MIDDLE AGED; PHOSPHODIESTERASE 5 INHIBITORS; PIPERAZINES; PURINES; RECEPTORS, ENDOTHELIN; SAFETY-BASED DRUG WITHDRAWALS; SCLERODERMA, SYSTEMIC; SULFONAMIDES; SULFONES; THIOPHENES;

EID: 84871383146     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/imj.12007     Document Type: Article

References (24)

1. Proudman SM, Stevens WM, Sahhar J, Celermajer D. Pulmonary arterial hypertension in systemic sclerosis: the need for early detection and treatment. Intern Med J 2007; 37: 485-494.
2. Condliffe R, Kiely DG, Peacock AJ, Corris PA, Gibbs JSR, Vrapi F etal. Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era. Am J Respir Crit Care Med 2009; 179: 151-157.
3. Koh ET, Lee P, Gladman DD, Abu-Shakra M. Pulmonary hypertension in systemic sclerosis: an analysis of 17 patients. Br J Rheumatol 1996; 35: 989-993.
4. Galie N, Hoeper MM, Humbert M, Torbicki A, Vachiery J-L, Barbera JA etal. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009; 30: 2493-2537.
5. Galie N, Hoeper MM, Gibbs JSR, Simonneau G. Liver toxicity of sitaxentan in pulmonary arterial hypertension. Eur Respir J 2011; 37: 475-476.
6. Barst RJ, Rich S, Widlitz A, Horn EM, McLaughlin V, McFarlin J. Clinical efficacy of sitaxsentan, an endothelin-A receptor antagonist, in patients with pulmonary arterial hypertension: open-label pilot study. Chest 2002; 121: 1860-1868.
7. Lee WTN, Kirkham N, Johnson MK, Lordan JL, Fisher AJ, Peacock AJ. Sitaxentan-related acute liver failure in a patient with pulmonary arterial hypertension. Eur Respir J 2011; 37: 472-474.
8. European Medicines Agency. Thelin (sitaxentan) to be withdrawn due to cases of unpredictable serious liver injury. [updated 10 Dec 2010; cited 2011 Sep 28]. Available from URL: http://www.ema.europa.eu/ema/index.jsp?curl=/pages/news_and_events/news/2010/12/news_detail_001161.jsp&murl=menus/news_and_events/news_and_events.jsp&mid=WC0b01ac058004d5c1
9. McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner Jr. etal. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation 2009; 119: 2250-2294.
10. Medicare Australia. Physician's guide: prescribing treatment for primary pulmonary hypertension and pulmonary arterial hypertension. [updated 1 Apr 2011; cited 2011 Aug 23]. Available from URL: http://www.medicareaustralia.gov.au/provider/pbs/drugs2/files/2293-physicians-guide.pdf
11. Channick RN, Simonneau G, Sitbon O, Robbins IM, Frost A, Tapson VF etal. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001; 358: 1119-1123.
12. Humbert M, Barst RJ, Robbins IM, Channick RN, Galie N, Boonstra A etal. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J 2004; 24: 353-359.
13. Galie N, Rubin L, Hoeper M, Jansa P, Al-Hiti H, Meyer G etal. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet 2008; 371: 2093-2100.
14. Galie N, Beghetti M, Gatzoulis MA, Granton J, Berger RMF, Lauer A etal. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation 2006; 114: 48-54.
15. Barst RJ, Langleben D, Badesch D, Frost A, Lawrence EC, Shapiro S etal. Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. J Am Coll Cardiol 2006; 47: 2049-2056.
16. Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A etal. Bosentan therapy for pulmonary arterial hypertension. [Erratum appears in N Engl J Med 2002 Apr 18; 346(16): 1258]. N Engl J Med 2002; 346: 896-903.
17. Galie N, Badesch D, Oudiz R, Simonneau G, McGoon MD, Keogh AM etal. Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2005; 46: 529-535.
18. Galie N, Olschewski H, Oudiz RJ, Torres F, Frost A, Ghofrani HA etal. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 2008; 117: 3010-3019.
19. Oudiz RJ, Galie N, Olschewski H, Torres F, Frost A, Ghofrani HA etal. Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension. J Am Coll Cardiol 2009; 54: 1971-1981.
20. McGoon MD, Frost AE, Oudiz RJ, Badesch DB, Galie N, Olschewski H etal. Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities. Chest 2009; 135: 122-129.
21. Galie N, Brundage BH, Ghofrani HA, Oudiz RJ, Simonneau G, Safdar Z etal. Tadalafil therapy for pulmonary arterial hypertension. Circulation 2009; 119: 2894-2903.
22. Galie N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D etal. Sildenafil citrate therapy for pulmonary arterial hypertension. [Erratum appears in N Engl J Med 2006 Jun 1; 354(22): 2400-1]. N Engl J Med 2005; 353: 2148-2157.
23. Barst RJ, Langleben D, Frost A, Horn E, Oudiz R, Shapiro S et al. Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med 2004; 169: 441-447.
24. Benza RL, Barst RJ, Galie N, Frost A, Girgis R, Highland K et al. Sitaxsentan for the treatment of pulmonary arterial hypertension: a 1-year, prospective, open-label observation of outcome and survival. Chest 2008; 134: 775-782.